Sarah Cannon Research Institute’s Post

Pleased to share our review on RET inhibitors - Vivek Subbiah, MD #Cancer #FDAApproval #NSCLC #OncoDaily #Oncology #Pralsetinib #PrecisionTherapy #Selpercatinib #ThyroidCancers

The latest Letter to Readers by Julie M. Vose, MD, MBA, discusses the most breaking presentation from American Society of Clinical Oncology (ASCO). https://lnkd.in/evY3svJZ #cancer #oncology

How DPD Deficiency Routine Testing Can Save Lives? - American Society of Clinical Oncology (ASCO) 24 Updates Ken Surprenant Advocates for Universal DPD/DPYD Testing Daniel Hertz #ASCO24Updates #DPDDeficiency #CancerPrevention #OncoDaily #Cancer #Oncology #CancerResearch

Tissue-agnostic precision medicine takes the spotlight! - Vivek Subbiah, MD American Society of Clinical Oncology (ASCO) #JCOPO #Cancer #EuropeanMedicinesAgency #FDA #Oncology #Selpercatinib #JournalOfClinicalOncology #OncoDaily  #PrecisionOncology 

Michelina Cairo, MD, Texas Oncology, discusses key insights from recent clinical trials for breast cancer, why she was excited to see a focus on patient quality of life at ASCO 2023, and more in this interview with OncLive. Check out the full interview below. #BreastCancer #QOL #CancerCare #ASCO23 #CommunityOncology

For patients with NSCLC, initial use of SGT increases subsequent CGP test cancellations - Vivek Subbiah, MD OncoAlert OncoDaily ESMO - European Society for Medical Oncology #Biomarkers #Cancer #CGPTest #ELCC24 #LungCancer #NSCLC #OncoDaily #Oncology

CDK4/6 Inhibitors as First-Line Options in Metastatic Breast Cancer: Expert perspectives on differentiating between the three CDK4/6 inhibitors available for the treatment of metastatic breast cancer are discussed, highlighting factors that inform treatment selection. #finance #pharmacy #lifesciences

At ESMO, we presented the data on PSA response, and how it correlates with survival. This interview with Dr. Neeraj Agarwal deeply analysis how PSA can be driven to unimagimable levels with Apalutamide. An interesting read for today!!

Olema Oncology is advancing the development of Palazestrant (OP-1250) in metastatic breast cancer in 2024. Palazestrant is an oral complete ER antagonist (CERAN) and selective ER degrader (SERD). It potently binds and completely blocks transcriptional activity of both wild-type and ESR1-mutant ER with favorable tolerability and anti-tumor activity. Palazestrant is under clinical development both in combination with Novartis' CDK4/6 inhibitor Kisqali (Ribociclib) as a first-line therapy for advanced estrogen receptor-positive, HER2-negative breast cancer, and as a monotherapy compared to standard of care treatment in second- and third-line advanced or metastatic ER-positive, HER2-negative breast cancer.  Chemenu supports your scientific research and drug discovery. Check our product catalog: https://lnkd.in/gt9hYaTw   #BC #BreastCancer #ER #CERAN #drugdevelopment #therapy #buildingblocks

A transformative “Vision for democratizing Next-Generation Oncology Clinical Trials” - Vivek Subbiah, MD https://lnkd.in/gCCVWzGa #oncodaily #oncology #cancer #AACR24 #OncologyClinicalTrials #NextGenOncology #InclusiveResearch #CancerConquerors #DemocratizeOncology